SpaceX set to bring more Starlink satellites into low Earth orbit
The 28 devices will ride a Falcon 9 that is scheduled to blast off at 8:22 p.m. EDT from Space Launch Complex 40 at Cape Canaveral Space Force Station in Brevard County, Florida.
This mission is the 470th Falcon 9 rocket launch, and if all goes as planned, its cargo will be added to the over 7,300 Starlink V2 Mini satellites already in low Earth orbit.
SpaceX will use the Falcon 9 first stage booster, tail number 1085, in what will be its seventh round-trip mission into space.
The craft will target a landing on the Just Read The Instructions, or JRTI drone ship, which will be stationed in the Atlantic Ocean. If successful, this will be the 442nd booster landing and 119th landing on JRTI.
The mission will be broadcast live on the SpaceX website, X TV app and X account. Backup launch times are possible and available until 12:22 a.m. EDT, or Wednesday starting at 7:30 EDT.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
UPI
a minute ago
- UPI
Microsoft reaches $4 trillion market value, joins Nvidia
Microsoft chairperson and CEO Satya Nadella speaks while in Tokyo, Japan in November of 2018. File Photo by Keizo Mori/UPI | License Photo July 31 (UPI) -- Microsoft jumped past the $4 trillion market value mark Thursday, joining Nvidia as only the second public company ever to achieve the financial feat. Its shares shot up almost 8% after the tech company reported earning $76.7 billion in revenue last quarter, with a net income earning of $27.2 billion, a 24% rise. It also showed that its Azure cloud computing platform is bringing in an annual $75 billion, growing 34% year-over-year. All these positive fiscal wins brought the company over $4 trillion in after-hours trading Wednesday, and after opening over that value Thursday, it became a member of a now-two-member club with Nvidia. Apple stands as the third most-valued company at around $3.2 trillion, but its stock has sunk so far in 2025, down around 17%. Its current financial status will be even clearer by the weekend, as it is slated to report its quarterly results Thursday after the closing bell. "Cloud and AI is the driving force of business transformation across every industry and sector," said Microsoft chairperson and CEO Satya Nadella in a press release Wednesday. "We're innovating across the tech stack to help customers adapt and grow in this new era, and this year, Azure surpassed $75 billion in revenue, up 34%, driven by growth across all workloads." The company declared itself "the leader in Cloud and AI infrastructure," in a social media post Wednesday.
Yahoo
28 minutes ago
- Yahoo
Why Rocket Lab (RKLB) Shares Keep Climbing to New Heights
July 31 - Rocket Lab (NASDAQ:RKLB) has drawn renewed attention from investors Climing more than 6% on Wednesday after a remarkable run in the past year, with shares climbing nearly 835% as the company advances in the competitive space launch market. The company's progress has lifted its market value to roughly $23 billion, making it a rising player alongside SpaceX. Warning! GuruFocus has detected 1 Warning Sign with ITONF. Rocket Lab operates the Electron rocket, which focuses on delivering small payloads to orbit and has become the second?most frequently launched U.S. rocket. Its next step is the medium?lift, reusable Neutron rocket, aimed at larger government and commercial missions. The U.S. Space Force selected Rocket Lab under its National Security Space Launch (NSSL) program, while the U.S. Air Force awarded a contract for a rocket?based point?to?point transportation test using Neutron. Analysts estimate Rocket Lab's 2025 revenue at $576 million and see potential growth as the company executes its early contracts. Future revenue could benefit from expanded government work and private?sector launches. While the stock has risen quickly, Rocket Lab's ability to establish Neutron as a reliable vehicle will determine whether it can close more of the gap with SpaceX in the years ahead. This article first appeared on GuruFocus. Sign in to access your portfolio
UPI
28 minutes ago
- UPI
Larger statin dosages urged for many with cholesterol, heart risks
1 of 2 | Dr. Charles Hennekens, a medical school professor and heart disease researcher at Florida Atlantic University in Boca Raton, Fla., says too many patients at high risk of heart attacks and stroke are being "underdosed" with beneficial statin drugs. Photo by Alex Dolce, Florida Atlantic University ST. PAUL, Minn., July 31 (UPI) -- Doctors are routinely "underdosing" statins for patients at risk for heart attacks and strokes due to elevated levels of "bad" cholesterol, even though the drugs have proven safe and effective, a top U.S. researcher maintains. At a time when an estimated 40% of U.S. adults have metabolic syndrome -- a combination of heart risk factors including obesity, hypertension, dyslipidemia and insulin resistance -- doctors usually don't start them off with the maximum dosage of statins, even though they can quickly lower levels of LDL cholesterol, according to an opinion published this month in the medical journal Trends in Cardiovascular Medicine. Co-author Dr. Charles Hennekens, the Sir Richard Doll Professor of Medicine and Preventive Medicine at Florida Atlantic University's Charles E. Schmidt College of Medicine in Boca Raton, says his analysis of several major clinical studies of the new generation of highly potent statins, such as rosuvastatin and atorvastatin, shows that maximal doses are safe and sorely needed, but aren't being prescribed. Those with metabolic syndrome have cardiovascular risks equivalent to those with prior heart attacks or strokes, yet many are "undertreated" by starting their statin regimens at low or moderate dosages, Hennekens told UPI. "The data indicate that over half of people who were put on a statin remain on the initial dose they're given, so even though the intent may be to titrate it up, it's not done in the majority of instances," he said. "So, you get on a low dose of statin and you stay on it." But this "flies at the face of the data" showing that statins "have the strongest and most consistent body of evidence supporting their prescription in treatment and prevention in both men and women including older adults," he said. "There's no threshold for LDL below which you don't see incremental benefits." The studies demonstrate newer statins can lower LDL, or bad cholesterol, in as quickly as a month and can provide related benefits, such as stabilizing the build-up of harmful plaque on the cells that line the interior surface of blood vessels, Hennekens said. Therefore, he urges cardiologists who initiate drug therapies for those with metabolic syndrome to start statins at maximal tolerated levels. "Everything points to getting on the highest dose of evidence-based statin," he noted. "The goal of LDL in the high-risk secondary patients is less than 50 [milligrams per deciliter], and we have a lot to do to achieve that goal because there are lots of forces in society, especially in American society, that are making that more difficult. "For example, in the United States today, in middle-age people gain 7 to 10 pounds of body weight every 10 years, so we have a society that's fatter, but only about 21% of Americans reach the daily minimum recommendation for daily physical activity, Hennekens said. "We have a nation that would benefit enormously from therapeutic lifestyle changes, but in the end, we have such high absolute risk that many are going to require adjunctive therapy." And if so, "we make a strong case that the first one you should consider is a statin, and that every other adjunctive therapy should be viewed in the context of residual risk after the statin is given with maximal doses," Hennekens added. Other experts on the use of statins to control LDL cholesterol contacted by UPI generally agreed with the premise that dosages should start at maximum levels for those at high risk of heart disease. Dr. Laurence Sperling, the Katz Professor in Preventive Cardiology at the Emory University School of Medicine in Atlanta, noted it's already on a list of guidelines developed in 2018 by an American College of Cardiology/American Heart Association joint task force. "In patients with clinical atherosclerotic cardiovascular disease, [the guidelines say] reduce LDL cholesterol with high-intensity statin therapy or maximally tolerated statin therapy," he said. "The more LDL cholesterol is reduced on statin therapy, the greater will be subsequent risk reduction." Sperling said he agreed with the recommendation to use "a maximally tolerated statin to lower LDL-C levels by 50%." Joseph Saseen, a researcher and professor of clinical pharmacy at the University of Colorado's Skaggs School of Pharmacy and Pharmaceutical Sciences in Boulder, told UPI one reason for the low-dosage prescriptions is that cardiologists overestimate the chances of possible side effects, such as muscle aches and digestive problems. "While dose-related side effects can occur, they do not justify the routine underdosing of statins in high-risk populations," Saseen said. "Clinicians too often initiate therapy at suboptimal doses, particularly in patients with elevated [cardiovascular] risk. Evidence-based guidelines recommend starting high-intensity statin therapy, especially very high-risk secondary prevention patients." Clinical data have shown, for instance, that initiating atorvastatin at as much as 80 mg. daily "is both safe and effective in reducing cardiovascular events among secondary prevention patients," Saseen said. "Similarly, rosuvastatin at 20 mg. has been shown to be a safe and effective starting dose in primary prevention patients with elevated [high-sensitivity C-reactive protein]." Also agreeing with Hennekens' conclusion is Dr. Paul Heidenreich, a practicing cardiologist, professor at the Stanford University School of Medicine and chief of medicine at the Palo Alto, Calif., Veterans Affairs clinic. "When high intensity statins are indicated, one can recommend starting with the high intensity or beginning with moderate intensity followed by up-titration," he said. He noted some cardiologists are concerned that if patients can't tolerate a high-intensity statin, they may subsequently refuse all statins, in which case it may be better to start off with a moderate dose. "However, I feel it is rare that the patient will refuse to try a lower dose," Heidenreich said. "As the authors note, titration to a higher intensity is not as frequent as it should be, with patients staying on the initial intensity. Thus, patients are likely better off starting with the recommended high-intensity statin." The clinical data also showed that the rate of intolerance with a placebo "was surprisingly high, suggesting that patients are on the lookout for any new symptom that occurs following initiation of a new medication. It is important to stress that the vast majority of patients tolerate statins medications without side effects," he said.
